Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/tirzepatide/new-jersey/jersey-city
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Jersey City, NJ

Verified Tirzepatide providers in Jersey City, NJ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
38
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: New Jersey
38 of 38 shown

Find a Tirzepatide provider in New Jersey.

Every entry is checked against the NPI registry and the New Jersey medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by New Jersey city · /tirzepatide/new-jersey/{city}
Newark
46 →
Paterson
30 →
§ 03Getting Tirzepatide in Jersey City
38 providers · Jersey City, NJ

How to get Tirzepatide in Jersey City.

38 GLP-1 prescribers and 7 local resource types are on record for Jersey City, plus 2 nearby towns in the directory.

Prescribers in Jersey City
38 prescribers
38 GLP-1 prescribers in Jersey City, most listed as Family Medicine (13), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (9). Any New Jersey-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Newark (46 providers) and Paterson (30 providers).
Around the prescription in Jersey City
7 listed nearby
6 dietitians, 4 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Jersey City.
Medicaid (weight loss)
Diabetes only
As of April 2026, New Jersey Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm New Jersey’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Jersey City

Jersey City, New Jersey has a population of 292,449 people. The adult obesity rate in Jersey City is an age-adjusted estimate of 26.6%, 1.1 percentage points below the New Jersey state rate of 27.7%. Diagnosed diabetes reaches 11.3% of adults in Jersey City. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 27.5% of adults in Jersey City.

of Jersey City adults have obesity
26.6%
diagnosed diabetes
11.3%
no regular physical activity
27.5%

Age-adjusted estimates for Jersey City, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic babies explained
§ 05Support around Tirzepatide in Jersey City
6 fitness clubs

The prescription is one part. Here is the rest, in Jersey City.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Jersey City, NJ, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Weehawken Waterfront Park and Recreation Center
REC CENTER
4.7 on Google · 1434 reviews
1 Port Imperial Blvd
Website
Evolution Fitness
FITNESS
4.8 on Google · 1050 reviews
102 Monroe St
Website
John F. Kennedy Recreation & Aquatic Center
REC CENTER
4.3 on Google · 685 reviews
211 W Kinney St
Website
Retro Fitness
FITNESS
3.8 on Google · 626 reviews
65-45 Otto Rd
Website
La Cancha Arena
CLUB
4.6 on Google · 611 reviews
45-01 Northern Blvd
Synergy Fitness Clubs
FITNESS
4.6 on Google · 605 reviews
1781 2nd Ave
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kirtee Agrawal, R.D
RD
Registered dietitian
1 River Ct
Call 917-628-4656NPI 1548474596
Amy Berkowitz, MS, RD, CNSC
RD
Registered dietitian
355 Grand St
Call 201-915-2000NPI 1649068040
Ariel Berkowitz
RD
Registered dietitian
1 Harborside Pl Apt 302
Call 201-421-0660NPI 1003779620
Jayne Berube, RD
RD
Registered dietitian
100 Dudley St Apt 2118
Call 718-753-8840NPI 1083921688
Anne Carroll, RDN
RD
Registered dietitian
2 2Nd St Apt 2103
Call 516-528-1788NPI 1114531571
Christine Caruso
RD
Registered dietitian
39 High St Apt 601
Call 303-877-8530NPI 1316806656
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in New Jersey

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in New Jersey
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in New Jersey
Clinics running GLP-1 programs, telehealth & in-person.
Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Tirzepatide in Alabama→Tirzepatide in Alaska→Tirzepatide in Arizona→Tirzepatide in Arkansas→Tirzepatide in California→Tirzepatide in Colorado→Tirzepatide in Connecticut→Tirzepatide in Delaware→Tirzepatide in Florida→Tirzepatide in Georgia→Tirzepatide in Hawaii→Tirzepatide in Idaho→Tirzepatide in Illinois→Tirzepatide in Indiana→Tirzepatide in Iowa→Tirzepatide in Kansas→Tirzepatide in Kentucky→Tirzepatide in Louisiana→Tirzepatide in Maine→Tirzepatide in Maryland→Tirzepatide in Massachusetts→Tirzepatide in Michigan→Tirzepatide in Minnesota→Tirzepatide in Mississippi→Tirzepatide in Missouri→Tirzepatide in Montana→Tirzepatide in Nebraska→Tirzepatide in Nevada→Tirzepatide in New Hampshire→Tirzepatide in New Jersey→Tirzepatide in New Mexico→Tirzepatide in New York→Tirzepatide in North Carolina→Tirzepatide in North Dakota→Tirzepatide in Ohio→Tirzepatide in Oklahoma→Tirzepatide in Oregon→Tirzepatide in Pennsylvania→Tirzepatide in Rhode Island→Tirzepatide in South Carolina→Tirzepatide in South Dakota→Tirzepatide in Tennessee→Tirzepatide in Texas→Tirzepatide in Utah→Tirzepatide in Vermont→Tirzepatide in Virginia→Tirzepatide in Washington→Tirzepatide in West Virginia→Tirzepatide in Wisconsin→Tirzepatide in Wyoming→
Related GLP-1 research
how tirzepatide titration works
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
oral and sublingual GLP-1 options
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Tirzepatide in New Jersey

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]